About half of the atypical hemolytic uremic syndrome (aHUS) patients had clinically relevant anxiety and more than a quarter met the criteria for post-traumatic stress disorder (PTSD), according to a recent study. “Our cross-sectional survey done a median of [six] years after acute … aHUS demonstrated a substantial burden…
Soliris (eculizumab) was effective in managing atypical hemolytic uremic syndrome (aHUS), which arose in a man as a side effect of chemotherapy treatment with gemcitabine. “The mainstay management decision [for gemcitabine-related aHUS] is the prompt discontinuation of gemcitabine therapy, and while this is effective in some patients, complement…
A substantial number of people with atypical hemolytic uremic syndrome (aHUS) carry rare structural variations in a part of the genome called the CFH-CFHR region and some variants are linked to certain disease manifestations, a recent study reports. “This work highlights the association between aHUS and genomic rearrangements in…
The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with a lower proportion of young children and a higher number of Black patients, a new study reports. “Further surveillance is required to determine if these trends continue,” the researchers wrote.
Soliris (eculizumab) can safely be discontinued in children with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission, but close monitoring is necessary due to the possibility of aHUS recurrence, a recent study in the Arabian Gulf region highlights. The study found that more than 70% of…
Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…
When treating atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab), the medication can be safely discontinued after the immune system disorder is in remission, a new study shows. Moreover, the results suggest that stopping Soliris, rather than continuing treatment indefinitely, can lead to substantial cost savings without notably…
Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS). The therapy, STP144G, is one of four experimental treatments developed with the proprietary Sirnaomics platform. Data from these early studies are expected to eventually…
Eight cases of atypical hemolytic uremic syndrome (aHUS) that occurred in people with underlying conditions that could have prompted increased activity of the complement cascade — a part of the immune system that is thought to drive aHUS — were described in a recent report. “The cases described…
The case of a woman who developed atypical hemolytic uremic syndrome (aHUS) during pregnancy was described in a recent report, which highlights the need to measure the levels of the ADAMTS13 enzyme to differentiate aHUS from similar conditions. The report, “A Case of Atypical Hemolytic Uremic…
Get regular updates to your inbox.